Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Opinion: For Medical Miracles and Innovation, Empower Life Sciences Companies — Don't Vilify Them

10/28/2016

0 Comments

 
Washington, DC — Former United States Senator Tom Coburn, MD, and Paul Howard, Ph.D., director of health policy, Manhattan Institute, and co-author of the new book, “Unlocking Precision Medicine,” write in The Hill:
 
"We can do virtually anything," Vice President Joe Biden told the Cleveland crowd. "Your children are going to see more progress in the next 15 years than we've seen in the last 75 years."
 
With these words, Biden opened the Cleveland Clinic’s medical innovation summit on Monday. The progress he spoke of is in the fight against cancer, where the next generation of American cures is set to radically shift the medical landscape.
 
While today’s tendency is to get mired in pitched battles over drug prices, reformers should focus their efforts on how best to bring these new cures to market — and get them in the hands of patients.
 
Tomorrow’s cures will be fueled largely by “precision medicine,” advanced treatments that zero in on the unique medical profiles of an individual patient, promising longer lives, better health, and, ultimately, less expensive care.
​“Because of technological advances,” noted Biden in his Cancer Moonshot update to the president last week, “researchers are now able to analyze cancer genes and proteins, along with other genes in the body, putting us closer than ever before to understanding what causes cancer and how to attack a particular cancer.”
 
The good news is that this medical revolution is within our grasp. Yet a widespread, ill-considered attack on pharmaceutical companies — critics of whom increasingly allege that drug manufacturers put a concern for corporate profits over the needs of those who require life-saving medicines — has endangered its progress.
 
A recent Kaiser Health Foundation poll found 77 percent of respondents think that drug costs are “unreasonable,” up from 72 percent just one year ago. And 78 percent favored limits on the amount companies can charge for high-cost medicines.
 
Critics’ indictment, however, badly misreads reality.
 
Truth be told, it’s hard to overstate how much society owes to the drug-makers who are allowing us to live longer, healthier, more productive lives.
 
It is perfectly understandable that Americans fret over the cost of prescription drugs. Being diagnosed with a devastating illness is traumatic in and of itself. Compound that stress with a financial shock and anyone would be overwhelmed.
 
The emotional resonance of that argument, however, all too often blinds critics to a more complex reality.
 
For one thing, the sky-high drug prices reported with such breathlessness by the media rarely reflect the actual costs to consumers. Moreover, the cost of treatment is rarely compared to the most relevant alternative — the cost of being sick.
 
Most importantly, the corresponding benefits of some of these drugs are truly breathtaking, as evidenced by dramatic breakthroughs in the treatments of diseases like HIV/AIDS and Hepatitis C, metastatic melanoma, and leukemia.
 
We can reduce drug costs by streamlining the regulatory process and allowing market forces to do what they do best: lower prices through the power of competition.
 
Where drug prices still remain high, insurers and drug companies need to develop new payment contracts that allow patients to access potentially life-saving treatments without having to worry about jeopardizing their financial future.
 
Payers and innovators should share risk — and reduce financial burdens on patients — by linking a drug’s price to its ability to improve and extend lives, or lower other health care costs.
 
The ultimate question here is a simple one: how do we maximize the number of Americans who have access to potentially life-saving, and life-extending, treatments? This is the central question of not only the Cancer Moonshot, but of forward-looking legislation in Congress like 21st Century Cures Act, which would accelerate the pace of new and innovative treatments.
 
Today’s discussion has been dominated by voices calling for quick fixes like capping drug prices or limiting the profits of pharmaceutical companies. While we have no doubt that many of those proposals are well-intentioned, they would have the practical effect of killing the golden goose.
 
Given the massive costs of bringing a successful drug to market (including costs for testing all the drugs that never make it to consumers), it is implausible to imagine that we could have more innovation while making it less attractive or profitable for innovators to pursue new treatments.
 
We reject the notion that Americans have to choose between a system that can rapidly bring new cures to market and one in which those cures are affordable. Indeed, any system worth having has to do both.
 
Policymakers ought to embrace reforms, be it the prudent recommendations of the Moonshot or 21st Century Cures, that allow medical innovation to flourish while also pursuing new contracting and payment strategies that lower access barriers for patients.
 
Saving the lives of thousands more cancer patients is well within our grasp – if only worry less about who to blame, and more about how to find a real path to better cancer cures.
 
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507